Sunitinib

MADRID — In this video, Toni Choueiri, MD, talked about “a very important study” from China in advanced renal cell carcinoma presented at ESMO Congress.

MADRID — In a video interview with Healio, Sumanta (Monty) Pal, MD, FASCO, spoke about the STELLAR-304 clinical trial for patients with non-clear cell renal cell carcinoma at ESMO Congress.

Adolescent and young adult survivors of kidney cancer appeared at significantly increased risk for left ventricular ejection fraction, according to study results published in Journal of the National Comprehensive Cancer Network.

A combination of lenvatinib and pembrolizumab continued to provide a greater survival benefit than sunitinib among patients with advanced renal cell carcinoma, an updated analysis of the randomized phase 3 CLEAR study showed.

SAN FRANCISCO — In this video, Moshe Ornstein, MD, highlights findings from the follow-up data of the CheckMate 9ER trial presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, highlights a biomarker analysis of CheckMate 9ER he presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Healio spoke with Toni K. Choueiri, MD, about follow-up data from the CheckMate 9ER presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Nivolumab plus cabozantinib extended OS and PFS compared with sunitinib as first-line treatment for patients with advanced renal cell carcinoma, according to updated results of the randomized phase 3 CheckMate 9ER trial.

Targeted cancer therapy had a higher association with risk for major adverse cardiovascular events than cytokine therapy among patients with advanced renal cell carcinoma, according to study results.

CHICAGO — Better health-related quality of life was linked to longer survival in patients with intermediate- or poor-risk renal cell carcinoma, according to an analysis of the CheckMate 214 trial.